指南与共识妇科生殖医学

世界子宫内膜异位症学会关于子宫内膜异位症分类的共识

World Endometriosis Society consensus on the classification of endometriosis.
指南 / 共识 · Hum Reprod · 2016-12-05

世界子宫内膜异位症学会于2014年4月30日召开共识会议,55名代表来自29个国家和国际组织,通过会前会后流程形成28条共识声明,其中10条获一致共识,2条未获多数共识。在更好的分类系统出现前,建议使用分类工具箱,包括修订版美国生殖医学学会分期系统,并在适当情况下使用Enzian和子宫内膜异位症生育指数分期系统。

要点

  • 共识会议形成28条声明,10条一致共识,2条未获多数共识。
  • 现有分类系统仅一个预测生育结局,均不能预测盆腔痛、药物反应、复发等。
  • 建议使用分类工具箱:修订版ASRM分期,适当情况下加Enzian和EFI分期系统。

核心结论

  • 在更好的分类系统开发前,建议所有外科医生在每次子宫内膜异位症手术中使用分类工具箱,包括修订版美国生殖医学学会分期系统,并在适当情况下使用Enzian和子宫内膜异位症生育指数分期系统。
  • 建议更广泛地使用世界子宫内膜异位症研究基金会子宫内膜异位症表型和生物样本库统一项目的手术和临床数据收集工具,以改善未来的分类,尤其在不进行手术时。

研究设计与样本

  • 共识会议于2014年4月30日与世界子宫内膜异位症学会第12届世界子宫内膜异位症大会同期举行。
  • 会议前后有严格流程,涉及来自多个学科的29个国家和国际、医学和非医学组织的55名代表。

主要发现

  • 共形成28条共识声明,其中10条获一致共识,没有一条声明在没有对声明强度或声明本身提出保留意见的情况下达成。
  • 2条声明未获多数共识。
  • 声明涵盖女性的优先事项、分类的各个方面、低资源的影响以及所有主要的子宫内膜异位症分类系统。

关键数值与推荐

  • 10条声明获一致共识,2条声明未获多数共识。
  • 建议使用分类工具箱,包括修订版美国生殖医学学会分期系统,并在适当情况下使用Enzian和子宫内膜异位症生育指数分期系统。
  • 建议更广泛地使用世界子宫内膜异位症研究基金会子宫内膜异位症表型和生物样本库统一项目的手术和临床数据收集工具。

临床怎么用

  • 作者建议所有外科医生在每次子宫内膜异位症手术中使用分类工具箱,包括修订版美国生殖医学学会分期系统,并在适当情况下使用Enzian和子宫内膜异位症生育指数分期系统。
  • 作者建议更广泛地使用世界子宫内膜异位症研究基金会子宫内膜异位症表型和生物样本库统一项目的手术和临床数据收集工具以改善未来分类,尤其在不进行手术时。

局限性

  • 该共识过程不同于正式指南制定过程,尽管基于相同的可用证据。
  • 参与该过程的不同国际专家组可能会产生细微不同的共识声明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the global consensus on the classification of endometriosis that considers the views of women with endometriosis? SUMMARY ANSWER: We have produced an international consensus statement on the classification of endometriosis through systematic appraisal of evidence and a consensus process that included representatives of national and international, medical and non-medical societies, patient organizations, and companies with an interest in endometriosis. WHAT IS KNOWN ALREADY: Classification systems of endometriosis, developed by several professional organizations, traditionally have been based on lesion appearance, pelvic adhesions, and anatomic location of disease. One system predicts fertility outcome and none predicts pelvic pain, response to medications, disease recurrence, risks for associated disorders, quality of life measures, and other endpoints important to women and health care providers for guiding appropriate therapeutic options and prognosis. STUDY DESIGN, SIZE, DURATION: A consensus meeting, in conjunction with pre- and post-meeting processes, was undertaken. PARTICIPANTS/MATERIALS, SETTING, METHODS: A consensus meeting was held on 30 April 2014 in conjunction with the World Endometriosis Society's 12th World Congress on Endometriosis. Rigorous pre- and post-meeting processes, involving 55 representatives of 29 national and international, medical and non-medical organizations from a range of disciplines, led to this consensus statement. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 28 consensus statements were made. Of all, 10 statements had unanimous consensus, however none of the statements was made without expression of a caveat about the strength of the statement or the statement itself. Two statements did not achieve majority consensus. The statements covered women's priorities, aspects of classification, impact of low resources, as well as all the major classification systems for endometriosis. Until better classification systems are developed, we propose a classification toolbox (that includes the revised American Society for Reproductive Medicine and, where appropriate, the Enzian and Endometriosis Fertility Index staging systems), that may be used by all surgeons in each case of surgery undertaken for women with endometriosis. We also propose wider use of the World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project surgical and clinical data collection tools for research to improve classification of endometriosis in the future, of particular relevance when surgery is not undertaken. LIMITATIONS, REASONS FOR CAUTION: This consensus process differed from that of formal guideline development, although based on the same available evidence. A different group of international experts from those participating in this process may have yielded subtly different consensus statements. WIDER IMPLICATIONS OF THE FINDINGS: This is the first time that a large, global, consortium-representing 29 major stake-holding organizations, from 19 countries - has convened to systematically evaluate the best available evidence on the classification of endometriosis and reach consensus. In addition to 21 international medical organizations and companies, representatives from eight national endometriosis organizations were involved, including lay support groups, thus generating and including input from women who suffer from endometriosis in an endeavour to keep uppermost the goal of optimizing quality of life for women with endometriosis. STUDY FUNDING/COMPETING INTERESTS: The World Endometriosis Society convened and hosted the consensus meeting. Financial support for participants to attend the meeting was provided by the organizations that they represented. There was no other specific funding for this consensus process. Mauricio Abrao is an advisor to Bayer Pharma, and a consultant to AbbVie and AstraZeneca; G David Adamson is the Owner of Advanced Reproductive Care Inc and Ziva and a consultant to Bayer Pharma, Ferring, and AbbVie; Deborah Bush has received travel grants from Fisher & Paykel Healthcare and Bayer Pharmaceuticals; Linda Giudice is a consultant to AbbVie, Juniper Pharmaceutical, and NextGen Jane, holds research grant from the NIH, is site PI on a clinical trial sponsored by Bayer, and is a shareholder in Merck and Pfizer; Lone Hummelshoj is an unpaid consultant to AbbVie; Neil Johnson has received conference expenses from Bayer Pharma, Merck-Serono, and MSD, research funding from AbbVie, and is a consultant to Vifor Pharma and Guerbet; Jörg Keckstein has received a travel grant from AbbVie; Ludwig Kiesel is a consultant to Bayer Pharma, AbbVie, AstraZeneca, Gedeon Richter, and Shionogi, and holds a research grant from Bayer Pharma; Luk Rombauts is an advisor to MSD, Merck Serono, and Ferring, and a shareholder in Monash IVF. The following have declared that they have nothing to disclose: Kathy Sharpe Timms; Rulla Tamimi; Hugh Taylor. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Johnson NP, Hummelshoj L, Adamson GD, et al. World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod. 2016. PMID: 27920089. doi:10.1093/humrep/dew293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。